Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ: ENTA )

6.280 +0.420 (+7.17%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 655,721
Open 5.840
Bid (Size) 5.700 (1)
Ask (Size) 6.280 (1)
Prev. Close 5.860
Today's Range 5.720 - 6.310
52wk Range 5.700 - 17.80
Shares Outstanding 21,055,392
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)
From Enanta Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-37.70%
-37.70%
1 Month
-32.55%
-32.55%
3 Month
-42.91%
-42.91%
6 Month
-48.61%
-48.61%
1 Year
-31.37%
-31.37%

More News

Read More
4 Analysts Assess Enanta Pharma: What You Need To Know
Via Benzinga
Enanta Pharma Earnings Analysis: Q4 Recap
Via Benzinga
Enanta Pharma Q4 Earnings Assessment
Via Benzinga
Insights into Enanta Pharma Q4 Earnings
Via Benzinga
Enanta Pharma: Q4 Earnings Insights
Via Benzinga
Earnings Breakdown: Enanta Pharma Q4
Via Benzinga
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For November 25, 2024
Via Benzinga
Enanta Pharma's Earnings Outlook
Via Benzinga
A Glimpse Into The Expert Outlook On Enanta Pharma Through 4 Analysts
Via Benzinga
Enanta Pharmaceuticals Reports Antiviral For Respiratory Syncytial Virus Reduces Virus Levels, Symptoms In Study
Via Benzinga
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Participate in Investor Conferences in September
From Enanta Pharmaceuticals, Inc.
Via Business Wire
ENTA Stock Earnings: Enanta Pharma Beats EPS, Beats Revenue for Q3 2024
Via InvestorPlace
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
ENTA Stock Earnings: Enanta Pharma Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.